Stock Evaluator: MBX Biosciences, Inc. (MBX)

MBX Biosciences, Inc. MBX

$68.57 1.49 2.22%
August 14, 2026 4:00:00 PM EST November 10, 2021 Volume: 503,134
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Commentary & Analysis


Financial Summary

Share Statistics MBX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,302.3 $587.7 60%
Shares Out (Mil) 47.7 44.5 46%
Institutional Ownership 96.9% 84.6% 72%
Float (Mil) 28.2 46.8 35%
Beta na 0.69 na
Avg Daily Volume (000s) 450 361 56%
Price Change
(52-week)
429.5% 66.7% 99%
Growth MBX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) na (1.4%) na
EPS (5yr) na 14.9% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (14.9%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 8 8
Current EPS ($0.845) ($3.108) ($3.942)
Month Ago EPS ($0.738) ($2.748) ($3.929)
# Rev Up 0 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.738) ($2.748) ($3.943)
Year/Year Chg 8.6% 30.5% 90.8%
Financials MBX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $276 na
Net Income (TTM) (Mil) ($104) ($11) 11%
EPS (TTM) ($2.405) ($0.700) 13%
Operating Cash Flow (TTM) (Mil) ($83) ($6) 7%
Net Cash Flow (TTM) (Mil) $15 $5 60%
Long-Term Debt (Q1) (Mil) $3 $6 21%
Enterprise Value (Q1) (Mil) na $309 na
Valuation MBX Industry
Median
Percentile
(All Stocks)
P/B 8.03 2.89 86%
P/E na 17.2 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios MBX Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.5% na
Net Margin na (2.3%) na
ROA (31.3%) (22.5%) 16%
ROE (33.2%) (19.8%) 19%
Liabilities to Assets 6.0% 32.4% 3%
F-Score 2 3 7%

Passing Stock Screens

As of 8/14/2026, from a list of 60 stock screening strategies, MBX meetings the criteria of 1 screen: